4.7 Review

Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease

期刊

出版社

MDPI
DOI: 10.3390/ijms222011243

关键词

microbiome; inflammatory bowel disease; ulcerative colitis; Crohn's disease; metabolomics; metagenomics; metatranscriptomics; microbiome therapeutics; clinical trials

资金

  1. NHMRC Australia [APP1162666]

向作者/读者索取更多资源

The intestinal microbiota is a complex ecosystem involving bacteria, fungi, archaea, and viruses, which plays crucial roles in maintaining homeostasis, immune regulation, and digestive function. While taxonomic shifts in the microbiota are associated with various diseases, particularly inflammatory bowel disease (IBD), further research is needed to understand the molecular mechanisms and utilize this resource for therapy. Advances in model systems have provided valuable insights into the functions of the microbiota and potential therapeutic candidates for IBD.
The intestinal microbiota is a complex community that consists of an ecosystem with a dynamic interplay between bacteria, fungi, archaea, and viruses. Recent advances in model systems have revealed that the gut microbiome is critical for maintaining homeostasis through metabolic digestive function, immune regulation, and intestinal barrier integrity. Taxonomic shifts in the intestinal microbiota are strongly correlated with a multitude of human diseases, including inflammatory bowel disease (IBD). However, many of these studies have been descriptive, and thus the understanding of the cause and effect relationship often remains unclear. Using non-human experimental model systems such as gnotobiotic mice, probiotic mono-colonization, or prebiotic supplementation, researchers have defined numerous species-level functions of the intestinal microbiota that have produced therapeutic candidates for IBD. Despite these advances, the molecular mechanisms responsible for the function of much of the microbiota and the interplay with host cellular processes remain areas of tremendous research potential. In particular, future research will need to unlock the functional molecular units of the microbiota in order to utilize this untapped resource of bioactive molecules for therapy. This review will highlight the advances and remaining challenges of microbiota-based functional studies and therapeutic discovery, specifically in IBD. One of the limiting factors for reviewing this topic is the nascent development of this area with information on some drug candidates still under early commercial development. We will also highlight the current and evolving strategies, including in the biotech industry, used for the discovery of microbiota-derived bioactive molecules in health and disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据